Biotech Firm Enzene Introduces New R&D Facility in Pune to Advance Scientific Research

Within the newly inaugurated centre, Enzene has set up several specialised departments which include cell line engineering (CLE), drug product development (DPD), purification process development (PPD), advanced analytical technology (AAT), and bioanalytical assay. 

Enzene Biosciences Ltd., a tech-driven Biotech company has recently unveiled its cutting-edge R&D centre in its headquartered city of Pune. 

Covering a span of over 75,000 square feet, this new R&D facility features an open lab set-up that facilitates collaboration among different departments. Moreover, it enhances communication among various teams and fosters the exchange of knowledge. 

The cutting-edge R&D centre aligns with the company's aim to enhance global healthcare by harnessing disruptive innovation. Besides, it also serves as a testament to the company's commitment to advancing scientific research and development.

Within the newly inaugurated centre, Enzene has set up several specialised departments which include cell line engineering (CLE), drug product development (DPD), purification process development (PPD), advanced analytical technology (AAT), and bioanalytical assay. 

The state-of-the-art R&D facility not only facilitates advanced research and development activities but also strengthens their expertise in these specialised areas,

Sharing his views on the augmentation, the CEO of Enzene, Himanshu Gadgil said, "We are thrilled to inaugurate this state-of-the-art facility which embodies our unwavering commitment to pioneering research and development." 

He continued to add, "The open lab setup is a testament to our belief in fostering a culture of collaboration, where ideas can flow freely, leading to transformative discoveries. Moreover, this facility will significantly enhance our capabilities to serve our valued CDMO partners with greater efficiency and excellence."

Expressing his views on the event, MD, Alkem Labs, Sandeep Singh said, "The inauguration of the R&D centre not only marks a momentous occasion for Enzene Biosciences but also highlights the company's dedication to elevating the biopharmaceutical landscape and delivering on its promise of driving positive impact in global healthcare," 

"These strategic developments will invigorate our plans to become a global CDMO player," he added.

Enzene Biosciences Ltd, the biological division of Alkem Laboratories, recognised the critical need for cost-effective discovery services to facilitate the development of affordable medicines for patients. Hence the company seeks to expand its reach into innovative sectors, including antibody-drug conjugates (ADC) and cell and gene therapies (CGT).

Furthermore, Enzene aims to provide partners with access to its 'œEnzeneX' technology offering a platform to help transform the concept of affordable drugs into a reality.

Enzene offers comprehensive services including cell line development, and fill & finish. Moreover, the tech-driven biotech company aims to facilitate seamless cross-functional interactions, by eliminating traditional barriers, a proven catalyst for creativity and drive innovation.

Enzene Biosciences aims to enhance collaborations with (Contract Development and Manufacturing Organisation (CDMO) clients by allowing them access to advanced technologies and expanding its range of services. Further, the company seeks to become a modality-agnostic biologics solution provider. 

Earlier, the company had introduced its own version of bevacizumab, its sixth biosimilar in over two years. Bevacizumab, originally sold by Roche under the brand Avastin, is utilised in the treatment of metastatic colorectal cancer.